Key result
Higher systolic BP variability linked to ~54% greater diabetic kidney disease progression per 1-point increase.
Why the study?
Blood pressure variability is a risk factor for kidney disease progression in hypertension and type 2 diabetes, but its role in type 1 diabetes was unknown.
Does blood pressure variability increase the risk of diabetic kidney disease progression in adults with type 1 diabetes?
Cohort (n=3,079)
Yes
Does blood pressure variability increase the risk of diabetic kidney disease progression in adults with type 1 diabetes?
Effect estimate: HR 1.54 (95% CI 1.27-1.87)
p-value: p=<0.001
In people with type 1 diabetes, increased systolic and diastolic blood pressure variability, as well as African Caribbean ethnicity, are independent risk factors for diabetic kidney disease progression.
BP variability assessment may refine DKD risk stratification in T1D; extends prior evidence and leaves open therapeutic targeting.
Aims/hypothesis Blood pressure variability (BPV) is a risk factor for kidney disease progression in hypertension and type 2 diabetes; however, the role of BPV in kidney disease in type 1 diabetes is unknown. The aim of this study was therefore to determine whether BPV has an impact on kidney disease progression in an ethnically diverse cohort of people with type 1 diabetes. Methods We studied 3079 people (median age 36 [range 18–85] years; 50% female; 78.5% White, 10.9% African Caribbean, 4.5% Asian, 6.1% Other) with type 1 diabetes and baseline eGFR >45 ml/min per 1.73m 2 attending two university hospital clinics between 2004 and 2018. BPV was assessed using visit-adjusted standard deviation (adj-SD), CV and average real variability (ARV) for systolic blood pressure (SBP) and diastolic blood pressure (DBP). The primary endpoint was eGFR decline of ≥50% from baseline with final eGFR <30 ml/min per 1.73m 2 , with death as a competing risk. Results Over a 14 year period, 272 people (8.8%) reached the primary endpoint. All BPV metrics for SBP and DBP were significantly associated with the primary endpoint. ARVs of SBP and DBP and African Caribbean ethnicity emerged as risk factors in multivariable analyses, independent of traditional risk factors, including baseline blood pressure, eGFR, HbA 1c , albuminuria and mean blood pressure in the exposure window. The strongest association was observed for the ARV of SBP (HR 1.54, 95% CI 1.27, 1.87, p <0.001). Conclusions/interpretation In people with type 1 diabetes, SBP and DBP variability are associated with kidney disease progression. Further studies are needed to investigate if BPV is a modifiable risk factor for kidney disease progression.
No takes yet. Share an insight, caveat, or question.
Ozdede et al. (2026) conducted a cohort in Type 1 diabetes (n=3,079). Blood pressure variability (ARV of SBP) vs. Lower blood pressure variability was evaluated on eGFR decline of ≥50% from baseline with final eGFR <30 ml/min per 1.73m2 (HR 1.54, 95% CI 1.27-1.87, p=<0.001). Each 1-point increase in log-adjusted average real variability of systolic blood pressure increased the risk of diabetic kidney disease progression by 54% (HR 1.54) in type 1 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: